Q11.DU Amaroq Ltd.

Basic Materials Gold Dusseldorf Exchange
1.23 EUR
Close of Oct 31, 2026
3.14 8.05
Market cap
EUR 557M
P/E
119.0x
P/B
2.79x
ROE
-7.6%
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is Q11.DU undervalued?

Graham number

The Graham number of Amaroq Ltd. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amaroq Ltd. fundamental analysis

3 of 21 checks passed

ROE 0/2

Low return on equity (-7.6%), below 10%.

ROA 1/1

Return on assets (-6.0%) is above the industry median (-11.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-1,765.7%) is below the industry median (-12.7%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.5 years of the current cash burn.

PE vs Market 0/1

PE (119.0x) is above the market median (18.2x).

PE vs Industry 0/1

PE (119.0x) is above the industry median (7.9x).

PBV 0/1

Price to book (2.8x) is above the industry median (2.7x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 332.3, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Amaroq Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amaroq Ltd.

Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.

Full company profile